GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » EV-to-EBIT

BETRF (BetterLife Pharma) EV-to-EBIT : -5.12 (As of May. 04, 2025)


View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BetterLife Pharma's Enterprise Value is $11.80 Mil. BetterLife Pharma's EBIT for the trailing twelve months (TTM) ended in Oct. 2024 was $-2.31 Mil. Therefore, BetterLife Pharma's EV-to-EBIT for today is -5.12.

The historical rank and industry rank for BetterLife Pharma's EV-to-EBIT or its related term are showing as below:

BETRF' s EV-to-EBIT Range Over the Past 10 Years
Min: -5.19   Med: 0   Max: 0
Current: -5.19

BETRF's EV-to-EBIT is ranked worse than
100% of 470 companies
in the Biotechnology industry
Industry Median: 8.29 vs BETRF: -5.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BetterLife Pharma's Enterprise Value for the quarter that ended in Oct. 2024 was $12.86 Mil. BetterLife Pharma's EBIT for the trailing twelve months (TTM) ended in Oct. 2024 was $-2.31 Mil. BetterLife Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2024 was -17.92%.


BetterLife Pharma EV-to-EBIT Historical Data

The historical data trend for BetterLife Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma EV-to-EBIT Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.32 -1.94 -1.57 -1.92 -5.26

BetterLife Pharma Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.78 -5.26 -4.74 -5.85 -6.40

Competitive Comparison of BetterLife Pharma's EV-to-EBIT

For the Biotechnology subindustry, BetterLife Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's EV-to-EBIT falls into.


;
;

BetterLife Pharma EV-to-EBIT Calculation

BetterLife Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=11.802/-2.305
=-5.12

BetterLife Pharma's current Enterprise Value is $11.80 Mil.
BetterLife Pharma's EBIT for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BetterLife Pharma  (OTCPK:BETRF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BetterLife Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Oct. 2024 ) =EBIT / Enterprise Value (Q: Oct. 2024 )
=-2.305/12.8621601
=-17.92 %

BetterLife Pharma's Enterprise Value for the quarter that ended in Oct. 2024 was $12.86 Mil.
BetterLife Pharma's EBIT for the trailing twelve months (TTM) ended in Oct. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BetterLife Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Barbara-jean Anne Bormann-kennedy director, officer: President 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong officer: Chief Financial Officer 2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari director, 10 percent owner 1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian director, officer: Chairman 1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6